Pharmadrug Inc. (CSE:PHRX)
Canada
· Delayed Price · Currency is CAD 0.0100
0.00 (0.00%)
May 13, 2025, 3:29 PM EDT
Pharmadrug Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Revenue | - | - | - | 0.01 | 0.68 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | -98.98% | 11.97% | Upgrade
|
| Cost of Revenue | - | - | 0 | 0.01 | 0.5 | Upgrade
|
| Gross Profit | - | - | -0 | -0 | 0.18 | Upgrade
|
| Selling, General & Admin | 0.4 | 0.78 | 1.27 | 1.55 | 2.06 | Upgrade
|
| Research & Development | 0.14 | 0.23 | 0.71 | 0.55 | - | Upgrade
|
| Operating Expenses | 0.63 | 1.36 | 2.35 | 2.72 | 4.13 | Upgrade
|
| Operating Income | -0.63 | -1.36 | -2.36 | -2.72 | -3.95 | Upgrade
|
| Interest Expense | - | -0.33 | -0.22 | -0.06 | -0.35 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | 0 | 0 | -0.73 | 0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.23 | -0.06 | -0.05 | -0.06 | -4.41 | Upgrade
|
| EBT Excluding Unusual Items | -0.86 | -1.76 | -2.62 | -3.57 | -8.6 | Upgrade
|
| Merger & Restructuring Charges | - | -1.43 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | -0.05 | -0.61 | -0.72 | 2.53 | Upgrade
|
| Asset Writedown | - | -10.14 | - | - | - | Upgrade
|
| Legal Settlements | - | 0.07 | -0.07 | - | - | Upgrade
|
| Other Unusual Items | - | -0.96 | 0.05 | - | 0.17 | Upgrade
|
| Pretax Income | -0.87 | -14.27 | -3.25 | -4.28 | -5.9 | Upgrade
|
| Income Tax Expense | - | -1.01 | -0.19 | - | -0.48 | Upgrade
|
| Earnings From Continuing Operations | -0.87 | -13.26 | -3.06 | -4.28 | -5.43 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -5.81 | -1.59 | - | Upgrade
|
| Net Income to Company | -0.87 | -13.26 | -8.88 | -5.87 | -5.43 | Upgrade
|
| Minority Interest in Earnings | 0.08 | 0.06 | - | 0.25 | 0.28 | Upgrade
|
| Net Income | -0.79 | -13.2 | -8.88 | -5.63 | -5.15 | Upgrade
|
| Net Income to Common | -0.79 | -13.2 | -8.88 | -5.63 | -5.15 | Upgrade
|
| Shares Outstanding (Basic) | 104 | 56 | 50 | 47 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 104 | 56 | 50 | 47 | 20 | Upgrade
|
| Shares Change (YoY) | 83.99% | 12.76% | 5.88% | 132.48% | 103.18% | Upgrade
|
| EPS (Basic) | -0.01 | -0.23 | -0.18 | -0.12 | -0.25 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.23 | -0.18 | -0.12 | -0.25 | Upgrade
|
| Free Cash Flow | -0.76 | -0.67 | -2.26 | -4.13 | -1.82 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.04 | -0.09 | -0.09 | Upgrade
|
| Gross Margin | - | - | - | -30.75% | 26.63% | Upgrade
|
| Operating Margin | - | - | - | -38806.68% | -578.02% | Upgrade
|
| Profit Margin | - | - | - | -80275.25% | -753.33% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -58906.35% | -266.35% | Upgrade
|
| EBITDA | -0.58 | -1.34 | -2.34 | -2.72 | -2.7 | Upgrade
|
| D&A For EBITDA | 0.05 | 0.03 | 0.01 | 0 | 1.26 | Upgrade
|
| EBIT | -0.63 | -1.36 | -2.36 | -2.72 | -3.95 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.